BR112020006012A2 - receptores de células t que reconhecem p53 mutado - Google Patents

receptores de células t que reconhecem p53 mutado Download PDF

Info

Publication number
BR112020006012A2
BR112020006012A2 BR112020006012-7A BR112020006012A BR112020006012A2 BR 112020006012 A2 BR112020006012 A2 BR 112020006012A2 BR 112020006012 A BR112020006012 A BR 112020006012A BR 112020006012 A2 BR112020006012 A2 BR 112020006012A2
Authority
BR
Brazil
Prior art keywords
seq
nos
amino acid
polypeptide chain
acid sequence
Prior art date
Application number
BR112020006012-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Drew C. DENIGER
Steven A. Rosenberg
Anna Pasetto
Rami Yoseph
Winifred M. Lo
Yong-Chen Lu
Maria R. Parkhurst
Paul F. Robbins
Parisa Malekzadeh
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of BR112020006012A2 publication Critical patent/BR112020006012A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112020006012-7A 2017-09-29 2018-09-17 receptores de células t que reconhecem p53 mutado BR112020006012A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565383P 2017-09-29 2017-09-29
US62/565,383 2017-09-29
PCT/US2018/051285 WO2019067243A1 (en) 2017-09-29 2018-09-17 T CELL RECEPTORS RECOGNIZING P53 MUTE

Publications (1)

Publication Number Publication Date
BR112020006012A2 true BR112020006012A2 (pt) 2020-10-06

Family

ID=63714167

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020006012-7A BR112020006012A2 (pt) 2017-09-29 2018-09-17 receptores de células t que reconhecem p53 mutado

Country Status (20)

Country Link
US (2) US11939365B2 (https=)
EP (2) EP4647442A3 (https=)
JP (3) JP7324193B2 (https=)
KR (2) KR20250024096A (https=)
CN (2) CN118955684A (https=)
AU (2) AU2018342246B2 (https=)
BR (1) BR112020006012A2 (https=)
CA (1) CA3077024A1 (https=)
CR (4) CR20200170A (https=)
DK (1) DK3688027T3 (https=)
EA (1) EA202090757A1 (https=)
ES (1) ES3056082T3 (https=)
FI (1) FI3688027T3 (https=)
IL (1) IL273515B2 (https=)
MA (1) MA50651A (https=)
MX (4) MX421596B (https=)
PL (1) PL3688027T3 (https=)
PT (1) PT3688027T (https=)
SG (1) SG11202002636PA (https=)
WO (1) WO2019067243A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
SG11202002635RA (en) * 2017-09-29 2020-04-29 The United States Of America As Represented By The Secretary Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
WO2020237368A1 (en) * 2019-05-27 2020-12-03 Provincial Health Services Authority Immunotherapy constructs targeting kras antigens
TW202525841A (zh) * 2019-06-27 2025-07-01 美國衛生與公眾服務部 識別p53中之r175h或y220c突變之t細胞受體
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
TWI900647B (zh) * 2020-09-04 2025-10-11 美國衛生與公眾服務部 識別p53中r273c或y220c突變的t細胞受體
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
JP2024517884A (ja) * 2021-05-07 2024-04-23 アメリカ合衆国 ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
JP2024540197A (ja) * 2021-10-29 2024-10-31 ホウ，ヤフェイ Ｐ５３におけるｒ１７５ｈ変異を認識するｔ細胞受容体およびその用途
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation
CN116063577B (zh) * 2022-11-18 2025-02-07 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2025024648A2 (en) * 2023-07-25 2025-01-30 Memorial Sloan-Kettering Cancer Center T cell receptors targeting tp53 hotspot mutations and uses thereof
WO2025060149A1 (zh) * 2023-09-22 2025-03-27 上海市第一人民医院 一种分离的tcr及其用途
WO2025226769A1 (en) * 2024-04-24 2025-10-30 Bluesphere Bio, Inc. T cell receptors targeting minor histocompatibility antigen lrh-1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770749B2 (en) 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
CA2487779C (en) * 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
HUE049292T2 (hu) * 2013-08-07 2020-09-28 Yeda Res & Dev A P53 mutánsok újraaktíválására képes peptidek
KR102375998B1 (ko) * 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
CA2945388A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
MX375379B (es) 2014-05-29 2025-03-06 Us Health Receptores de celulas t anti - papilomavirus 16 e7 humano.
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
AU2014407539B2 (en) * 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
EP3265079A4 (en) 2015-03-03 2019-01-02 Caris MPI, Inc. Molecular profiling for cancer
WO2016179006A1 (en) * 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
US11047011B2 (en) * 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use

Also Published As

Publication number Publication date
MX421596B (es) 2025-03-14
IL273515B2 (en) 2026-03-01
PL3688027T3 (pl) 2026-04-07
AU2018342246A1 (en) 2020-04-16
EP3688027B1 (en) 2025-09-10
KR20250024096A (ko) 2025-02-18
EP4647442A3 (en) 2026-03-04
MX2024005676A (es) 2024-06-11
CN118955684A (zh) 2024-11-15
CN111386282B (zh) 2024-09-06
IL273515A (en) 2020-05-31
ES3056082T3 (en) 2026-02-18
AU2024227695A1 (en) 2024-12-05
US11939365B2 (en) 2024-03-26
IL273515B1 (en) 2025-11-01
MA50651A (fr) 2020-08-05
AU2018342246B2 (en) 2024-08-08
KR102762272B1 (ko) 2025-02-07
CR20240303A (es) 2024-09-04
JP2025020145A (ja) 2025-02-12
JP2023159112A (ja) 2023-10-31
KR20200064110A (ko) 2020-06-05
CR20200170A (es) 2020-11-23
PT3688027T (pt) 2025-12-16
JP7573075B2 (ja) 2024-10-24
FI3688027T3 (fi) 2025-12-09
JP2021500010A (ja) 2021-01-07
SG11202002636PA (en) 2020-04-29
WO2019067243A1 (en) 2019-04-04
CN111386282A (zh) 2020-07-07
MX2020003504A (es) 2020-09-14
JP7324193B2 (ja) 2023-08-09
CR20240302A (es) 2024-11-07
US20200277352A1 (en) 2020-09-03
JP7814467B2 (ja) 2026-02-16
CR20250153A (es) 2025-06-03
CA3077024A1 (en) 2019-04-04
MX2024005677A (es) 2024-06-11
EP3688027A1 (en) 2020-08-05
EP4647442A2 (en) 2025-11-12
MX2024005678A (es) 2024-06-11
EA202090757A1 (ru) 2020-08-21
DK3688027T3 (da) 2025-12-15
US20240270814A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
BR112020006012A2 (pt) receptores de células t que reconhecem p53 mutado
Ye et al. miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1
Kang et al. A novel role for the mitochondrial HTRA2/OMI protease in aging
WO2011063005A3 (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
Feng et al. H19/miR-130a-3p/DAPK1 axis regulates the pathophysiology of neonatal hypoxic-ischemia encephalopathy
Saliba et al. Probing the acceptor active site organization of the human recombinant β1, 4-galactosyltransferase 7 and design of xyloside-based inhibitors
Fagagnini et al. Onconase dimerization through 3D domain swapping: structural investigations and increase in the apoptotic effect in cancer cells
Ahmad et al. Miro 1 knockdown in stem cells inhibits mitochondrial donation mediated rescue of bronchial epithelial injury
Zhou et al. MicroRNA-138 directly targets TNFAIP8 and acts as a tumor suppressor in osteosarcoma
Dong et al. Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer
Liu et al. Decreased miR-208 induced ischemia myocardial and reperfusion injury by targeting p21
Wang et al. KLF5 is involved in regulation of IFITM1, 2, and 3 genes during H5N1 virus infection in A549 cells
Miyazaki et al. NS1-binding protein abrogates the elevation of cell viability by the influenza A virus NS1 protein in association with CRKL
Guo et al. MicroRNA-26a regulates cerebral ischemia injury through targeting PTEN.
LI Effect and mechanism of allomatrine in proliferation and invasion in vitro inhibition of human lung cancer A549 cell line
Zhang et al. Overexpression of long non-coding RNA GASL1 induces apoptosis and G0/G1 cell cycle arrest in human oral cancer cells
Möncke-Buchner et al. Sin Nombre hantavirus nucleocapsid protein exhibits a metal-dependent DNA-specific endonucleolytic activity
Tohyama et al. Endoplasmic reticulum stress-induced keratinocyte necrosis is a new mechanism of epidermal cell death in SJS/TEN
Wang et al. Kaempferol Promotes Apoptosis and Inhibited Autophagy in A549 Cells via MicroRNA-199/Mammalian Target of Rapamycin Axis.
Alexoudi et al. Alternating hemiplegia of childhood and rapid‐onset dystonia parkinsonism are allelic disorders due to ATP1A3 gene mutations
You et al. LncRNA WT1-AS Attenuates hypoxia/ischemia Induced Neuronal Injury in Cerebral Ischemic Stroke via miR-186-5p/XIAP Axis
Kong et al. Inhibition of Beclin 1 enhances apoptosis by H2O2 in glioma U251 cells
Chenghua et al. Expression analysis of groEL of Candidatus Liberibacter asiaticus and antibody preparation
FAN et al. Hsa-mir-202 inhibit the proliferation of lung cancer A549 cells by reducing expression of IL-10
HUANG An in vitro study of the relationship between KiSS-1 expression and hepatoma carcinoma cell proliferation, adhesion, and invasion

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]